scholarly journals 925A Normal Transthoracic Echocardiogram can be Used to Rule Out Infective Endocarditis in Patients with Staphylococcus aureus Bacteremia

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S267-S267
Author(s):  
Adrienne Showler ◽  
Lisa Burry ◽  
Anthony Bai ◽  
Daniel Ricciuto ◽  
Marilyn Steinberg ◽  
...  
2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Poorani Sekar ◽  
James R. Johnson ◽  
Joseph R. Thurn ◽  
Dimitri M. Drekonja ◽  
Vicki A. Morrison ◽  
...  

Abstract Background Echocardiography is fundamental for diagnosing infective endocarditis (IE) in patients with Staphylococcus aureus bacteremia (SAB), but whether all such patients require transesophageal echocardiography (TEE) is controversial. Methods We identified SAB cases between February 2008 and April 2012. We compared sensitivity and specificity of transthoracic echocardiography (TTE) and TEE for evidence of IE, and we determined impacts of IE risk factors and TTE image quality on comparative sensitivities of TTE and TEE and their impact on clinical decision making. Results Of 215 evaluable SAB cases, 193 (90%) had TTE and 130 (60%) had TEE. In 119 cases with both tests, IE was diagnosed in 29 (24%), for whom endocardial involvement was evident in 25 (86%) by TEE, vs only 6 (21%) by TTE (P < .001). Transesophageal echocardiography was more sensitive than TTE regardless of risk factors. Even among the 66 cases with adequate or better quality TTE images, sensitivity was only 4 of 17 (24%) for TTE, vs 16 of 17 (94%) for TEE (P < .001). Among 130 patients with TEE, the TEE results, alone or with TTE results, influenced treatment duration in 56 (43%) cases and led to valve surgery in at least 4 (6%). It is notable that, despite vigorous efforts to obtain both tests routinely, TEE was not done in 86 cases (40%) for various reasons, including pathophysiological contraindications (14%), patient refusal or other patient-related factors (16%), and provider declination or system issues (10%). Conclusions Patients with SAB should undergo TEE when possible to detect evidence for IE, especially if the results might affect management.


2007 ◽  
Vol 82 (10) ◽  
pp. 1165-1169 ◽  
Author(s):  
Evelyn E. Hill ◽  
Steven Vanderschueren ◽  
Jan Verhaegen ◽  
Paul Herijgers ◽  
Piet Claus ◽  
...  

2004 ◽  
Vol 43 (5) ◽  
pp. A394
Author(s):  
Anne Marie Valente ◽  
Rajiv Jain ◽  
Mark Scheurer ◽  
Vance Fowler ◽  
G Ralph Corey ◽  
...  

2003 ◽  
Vol 47 (11) ◽  
pp. 3400-3406 ◽  
Author(s):  
John Vernachio ◽  
Arnold S. Bayer ◽  
Thuan Le ◽  
Yin-Li Chai ◽  
Bradley Prater ◽  
...  

ABSTRACT SA-IGIV is a human polyclonal immunoglobulin containing elevated levels of antibodies specific for the fibrinogen-binding MSCRAMM protein clumping factor A (ClfA). In vitro, SA-IGIV specifically recognized ClfA that was expressed on the surface of Staphylococcus aureus and inhibited bacterial adherence to immobilized human fibrinogen by >95%. Moreover, SA-IGIV efficiently opsonized ClfA-coated fluorescent beads and facilitated phagocytosis by human polymorphonuclear leukocytes. To determine its potential therapeutic efficacy, SA-IGIV was evaluated in combination with vancomycin in a rabbit model of catheter-induced aortic valve infective endocarditis (IE) caused by methicillin-resistant S. aureus (MRSA). The combination therapy was more effective than vancomycin alone in sterilizing all valvular vegetations when used therapeutically during early (12-h) IE. The combination therapy resulted in clearance of bacteremia that was significantly faster than that of vancomycin alone in animals with well-established (24-h) IE. Therefore, in both early and well-established MRSA IE, the addition of SA-IGIV to a standard antibiotic regimen (vancomycin) increased bacterial clearance from the bloodstream and/or vegetations.


Sign in / Sign up

Export Citation Format

Share Document